Search results for: Oncology
Filter search results
Quality of Life in Long-term Cancer Survivors: Implications for Future Health Technology Assessments in Oncology
3 July 2018
…Summers, Y. and Devlin, N. 2018. Quality of Life in Long-term Cancer Survivors: Implications for Future Health Technology Assessments in Oncology. OHE Consulting Report, London: Office of Health Economics. RePEc…
Time to Tackle the Challenges around Combination Therapies for Cancer
29 March 2021
…market, often at prices presenting challenges to payers around the world. Indeed, experts agree combination therapies will become increasingly important in oncology. A new Editorial, Not Cost-effective at Zero Price,…
Achieving Accelerated Patient Access to Cancer Care in Europe
3 November 2025
…through a structured, multidisciplinary stakeholder engagement process. APACE focuses on oncology treatments for conditions with significant unmet need that lack mature evidence for conventional HTA and P&R pathways, and outlines…
How long are patients WAITing for new treatments?
2 July 2026
…of this issue, during the period covered by the W.A.I.T. report, there were 33 NICE technology appraisals for oncology combination therapies, representing 20% of the 161 oncology treatments appraised by…
Bridging the Gap: Pathways for Regulatory and Health Technology Assessment of Histology Independent Cancer Treatments
8 January 2021
Histology independent therapies represent a new era in how oncology patients are diagnosed and treated, by targeting a genomic alteration within all solid tumours regardless of where the primary tumour…
NICE at 25: Technology Appraisals – Faster Access to Modern Treatment?
1 May 2024
…oncology treatments was put in place in 2011, with the establishment of a £200m dedicated fund for new oncology medicines not recommended by NICE. The rationale for this was twofold:…
Using Target Product Profiles (TPPs) to improve diagnostic testing for cancer
10 June 2024
In order to improve the diagnostic landscape in oncology and address a known gap or limitation in current diagnostic tools, a Target Product Profile (TPP) could be used as a…
A global landscape analysis of access to tumour-agnostic therapies
1 December 2025
Share this: Download publication Henry Fong Priscila Radu Nadine Henderson Martina Garau Lotte Steuten Key messages Tumour-agnostic (TA) therapies disrupt conventional oncology paradigms by targeting molecular alterations rather than tumour…
Can a continued focus on prevention, diagnosis, and treatment see the NHS to another 75 years?
27 July 2023
…1995–2014 (ICBP SURVMARK-2): a population-based study” The Lancet Oncology Progress in cancer survival, mortality, and incidence in seven high-income countries 1995–2014 (ICBP SURVMARK-2): a population-based study – The Lancet Oncology…